儿科后重症监护综合征和当前的治疗选择
Cydni N Williams1, Neethi P Pinto2, Gillian A Colville3
1Division of Pediatric Critical Care, Department of Pediatrics, Pediatric Critical Care and Neurotrauma Recovery Program, 707 SW Gaines Street, CDRC-P, Portland, OR 97239, USA.
Critical care clinics
|November 15, 2024
概括
后重症监护综合征 (PICS) 影响了多个健康领域的大多数儿科重症监护幸存者. 解决儿童的独特挑战需要专门的方法和多学科的诊所,以进行有效的干预.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 儿科的幸存者研究.
- 神经发育障碍 神经发育障碍
背景情况:
- 后重症监护综合征 (PICS) 是一种普遍影响重症监护的幸存者的疾病.
- 皮克斯包括身体,认知,情绪和社会健康障碍.
- 由于与年龄相关的生物差异,疾病变异性和环境因素,儿科PICS存在独特的挑战.
研究的目的:
- 突出儿童幸存者的PICS多方面的性质.
- 要强调诊断和管理儿童PICS的具体挑战.
- 强调儿童PICS的日益增长的认可和干预机会.
主要方法:
- 关于儿科重症监护生存率的新兴文献的综述.
- 分析儿科患者群体和神经发育阶段的异质性.
- 对儿童PICS发病率缺乏标准化的测量方法的检查.
主要成果:
- 皮克斯会影响儿科幸存者的身体,认知,情感和社会健康.
- 儿科PICS诊断和治疗因年龄,疾病,环境和测量问题而复杂.
- 专门的多学科诊所正在出现,以解决儿科PICS.
结论:
- 儿科PICS是一个重大问题,需要定制的干预措施.
- 多学科的方法对于在儿科生存中管理PICS至关重要.
- 需要进一步的研究和标准化工具来改善儿科PICS结果.
相关概念视频
Acute Respiratory Failure-V
123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Pneumonia IV: Management
299
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
299
Flail Chest-II
160
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
160
Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
153
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
153


